Claims for Patent: 7,728,118

Summary for Patent: 7,728,118

Title:	Synthetic nucleic acid molecule compositions and methods of preparation
Abstract:	A method to prepare synthetic nucleic acid molecules having reduced inappropriate or unintended transcriptional characteristics when expressed in a particular host cell.
Inventor(s):	Wood; Keith V. (Mt. Horeb, WI), Wood; Monika G. (Mt. Horeb, WI), Almond; Brian (Fitchburg, WI), Paguio; Aileen (Madison, WI), Fan; Frank (Madison, WI)
Assignee:	Promega Corporation (Madison, WI)
Application Number:	10/943,508
Patent Claims:	1. An isolated nucleic acid molecule comprising a synthetic nucleotide sequence having a coding region for a selectable polypeptide, wherein the synthetic nucleotide sequence has 90% or less nucleic acid sequence identity to a wild-type or parent nucleic acid sequence encoding a corresponding selectable polypeptide which, when expressed in a cell, confers resistance to puromycin, hygromycin-or neomycin, wherein the decreased sequence identity is a result of different codons in the synthetic nucleotide sequence relative to the codons in the wild-type or parent nucleic acid sequence, wherein the synthetic nucleotide sequence encodes a selectable polypeptide with at least 85% amino acid sequence identity to the corresponding selectable polypeptide encoded by the wild-type or parent nucleic acid sequence, wherein the synthetic nucleotide sequence has a reduced number of regulatory sequences including a reduced number of a combination of different vertebrate transcription factor binding sequences and of promoter modules relative to the number of regulatory sequences in a derivative of the wild-type or parent nucleic acid sequence in which native codons are replaced with high usage mammalian codons, as a result of selecting mammalian codons as the different codons so as to reduce the number of regulatory sequences, and wherein the synthetic nucleotide sequence, when expressed in a cell, confers resistance to puromycin, hygromycin or neomycin, wherein the synthetic nucleotide sequence has at least 90% or more nucleic acid sequence identity to SEQ ID NO:11, SEQ ID NO:71 or SEQ ID NO:73, or the complete complement thereof. 2. The isolated nucleic acid molecule of claim 1 wherein the regulatory sequences include transcription factor binding sequences, intron splice sites, poly(A) sites, promoter modules, and/or promoter sequences. 3. The isolated nucleic acid molecule of claim 1 wherein the nucleic acid molecule encodes a fusion of the selectable polypeptide with a luciferase. 4. The isolated nucleic acid molecule of claim 3 wherein the luciferase is a Renilla luciferase, a firefly luciferase or a click beetle luciferase. 5. The isolated nucleic acid molecule of claim 1 wherein the parent nucleic acid sequence is a wild-type neo, hyg, or pure sequence. 6. The isolated nucleic acid molecule of claim 1 wherein the parent nucleic acid sequence is SEQ ID NO:1, SEQ ID NO:6, or SEQ ID NO:15. 7. The isolated nucleic acid molecule of claim 1 wherein the synthetic nucleotide sequence comprises an open reading frame in SEQ ID NO:11, SEQ ID NO:71, or SEQ ID NO:73. 8. The isolated nucleic acid molecule of claim 1 wherein the synthetic nucleotide sequence has at least 10% fewer regulatory sequences. 9. The isolated nucleic acid molecule of claim 1 wherein the synthetic nucleotide sequence has an increased number of AGC seine-encoding codons, an increased number of ATC isoleucine-encoding codons, an increased number of CCC proline-encoding codons, and/or an increased number of ACC threonine-encoding codons. 10. The isolated nucleic acid molecule of claim 1 wherein the codons in the synthetic nucleotide sequence which differ encode the same amino acids as the corresponding codons in the parent nucleic acid sequence. 11. The isolated nucleic acid molecule of claim 1 wherein the nucleic acid molecule encodes a fusion of the selectable polypeptide with one or more other peptides or polypeptides, wherein at least the selectable polypeptide is encoded by the synthetic nucleic acid sequence. 12. The isolated nucleic acid molecule of claim 11 wherein one or more other peptides are peptides having protein destabilization sequences. 13. A plasmid comprising the nucleic acid molecule of claim 1. 14. The plasmid of claim 13 which further comprises a multiple cloning region. 15. The plasmid of claim 13 which further comprises an open reading frame of interest. 16. The plasmid of claim 13 which further comprises a promoter functional in a particular host cell operably linked to the synthetic nucleotide sequence. 17. The plasmid of claim 16 wherein the promoter is functional in a prokaryotic cells. 18. The plasmid of claim 16 wherein the promoter is functional in a eukaryotic cell. 19. The plasmid of claim 15 further comprising a promoter operably linked to the open reading frame of interest. 20. A synthetic nucleotide sequence of at least 100 nucleotides having a coding region for a selectable polypeptide which confers resistance to puromycin, hygromycin or neomycin, wherein the synthetic nucleotide sequence has 90% or less nucleic acid sequence identity to a corresponding region of a wild-type parent nucleic acid sequence for the selectable polypeptide, wherein the decreased sequence identity is a result of different codons in the synthetic nucleotide sequence relative to the codons in the corresponding region in the parent nucleic acid sequence, wherein the synthetic nucleotide sequence has a reduced number of regulatory sequences including a reduced number of a combination of different vertebrate transcription factor binding sequences and of promoter modules relative to the number of regulatory sequences in a derivative of the wild-type nucleic acid sequence in which native codons are replaced with high usage mammalian codons, as a result of selecting mammalian codons as the different codons so as to reduce the number of regulatory sequences, wherein the synthetic nucleotide sequence has at least 90% or more nucleic acid sequence identity to SEQ ID NO:11, SEQ ID NO:71 or SEQ ID NO:73, or the complete complement thereof. 21. An isolated nucleic acid molecule encoding a selectable polypeptide and comprising a synthetic nucleotide sequence of at least 100 nucleotides having a coding region for the selectable polypeptide when expressed in a cell, confers resistance to puromycin, hygromycin or neomycin, wherein the synthetic nucleotide sequence has 90% or less nucleic acid sequence identity to a corresponding region in a wild-type or parent nucleic acid sequence for the selectable polypeptide, wherein the decreased sequence identity is a result of different codons in the synthetic nucleotide sequence relative to the codons in the wild-type or parent nucleic acid sequence, wherein the synthetic nucleotide sequence encodes a region of the selectable polypeptide with at least 90% amino acid sequence identity to the corresponding region of the selectable polypeptide encoded by the wild-type or parent nucleic acid sequence, wherein the synthetic nucleotide sequence has a reduced number of regulatory sequences including a reduced number of a combination of different vertebrate transcription factor binding sequences and of promoter modules relative to the number of regulatory sequences in a derivative of the wild-type or parent nucleic acid sequence in which native codons are replaced with high usage mammalian codons, as a result of selecting mammalian codons as the different codons so as to reduce the number of regulatory sequences, and wherein the isolated nucleic acid molecule, when expressed in a cell, confers resistance to puromycin, hygromycin or neomycin, wherein the synthetic nucleotide sequence has at least 90% or more nucleic acid sequence identity to SEQ ID NO:11, SEQ ID NO:71 or SEQ ID NO:73, or the complete complement thereof. 22. The isolated nucleic acid molecule of claim 1 wherein the parent nucleic acid sequence has SEQ ID NO:1. 23. The isolated nucleic acid molecule of claim 1 wherein the parent nucleic acid sequence encodes SEQ ID NO:2. 24. An isolated nucleic acid molecule which has at least 90% nucleotide sequence identity to an open reading frame in any one of SEQ ID NO:11, SEQ ID NO:71, or SEQ ID NO:73, which open reading frame, when expressed in a cell, confers resistance to neomycin, or the complete complement thereof. 25. The isolated nucleic acid molecule of claim 24 which has any one of SEQ ID NO:11, SEQ ID NO:71, or SEQ ID NO:73, or the complete complement thereof. 26. The isolated nucleic acid molecule of claim 24 wherein the open reading frame has codons that are different than those in a wild-type parent nucleic acid sequence encoding a polypeptide that confers puromycin, hygromycin or neomycin resistance, which different codons reduce the number of different vertebrate transcription factor binding sequences and promoter modules. 27. The isolated nucleic acid molecule of claim 24 wherein the nucleic acid molecule encodes a fusion of one or more peptides or polypeptides with the polypeptide that confers neomycin resistance. 28. A plasmid comprising the isolated nucleic acid molecule of claim 24. 29. The plasmid of claim 28 which further comprises a multiple cloning region. 30. The plasmid of claim 28 which further comprises an open reading frame of interest. 31. The plasmid of claim 28 which further comprises a promoter functional in a particular host cell operably linked to the synthetic nucleotide sequence. 32. The plasmid of claim 31 wherein the promoter is functional in a eukaryotic cell. 33. The plasmid of claim 30 further comprising a promoter operably linked to the open reading frame of interest. 34. The isolated nucleic acid molecule of claim 26 wherein the parent nucleic acid sequence has SEQ ID NO: 1. 35. The isolated nucleic acid molecule of claim 1 or 21 wherein the synthetic nucleotide sequence has at least 90% or more nucleic acid sequence identity to SEQ ID NO:73 or the complete complement thereof. 36. The synthetic nucleotide sequence of claim 20 which has at least 90% or more nucleic acid sequence identity to SEQ ID NO:73 or the complete complement thereof.

Details for Patent 7,728,118

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2039-02-26
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2039-02-26
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2039-02-26